| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
2,250,000,000 |
| Market
Cap: |
100.91(B) |
| Last
Volume: |
21,280,549 |
Avg
Vol: |
11,944,728 |
| 52
Week Range: |
$44.7 - $69.08 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 100 |
|
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 11.3 |
| Insider 3/6 Months : 11.9 |
|
| Guru Rank Number : 97 |
| Guru Rank Value : 8.6 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
13,571 |
13,571 |
13,571 |
| Total Buy Value |
$0 |
$672,994 |
$672,994 |
$672,994 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
3 |
3 |
3 |
| Total Shares Sold |
0 |
0 |
69,103 |
681,397 |
| Total Sell Value |
$0 |
$0 |
$4,525,215 |
$49,727,684 |
| Total People Sold |
0 |
0 |
3 |
6 |
| Total Sell Transactions |
0 |
0 |
3 |
12 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Samuels Theodore R. Ii |
Director |
– • – |
2023-11-20 |
4 |
B |
$49.81 |
$423,385 |
D/D |
8,500 |
35,500 |
2.39 |
8% |
|
| Caforio Giovanni |
Board Chair and CEO |
• • – |
2023-10-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
440 |
367,495 |
|
- |
|
| Gallman Cari |
EVP, Corporate AffairsOfficer |
• – – |
2023-10-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
206 |
|
-14% |
|
| Judge Ann Powell |
EVP, Chief Human Resources |
• – – |
2023-08-24 |
4 |
S |
$61.25 |
$1,101,643 |
D/D |
(17,986) |
27,868 |
|
15% |
|
| Plenge Robert M |
EVP, Chief Research Officer |
• – – |
2023-08-03 |
4 |
S |
$61.14 |
$44,754 |
D/D |
(732) |
6,584 |
|
17% |
|
| Plenge Robert M |
EVP, Chief Research OfficerOff |
• – – |
2023-07-03 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
200 |
|
-19% |
|
| Plenge Robert M |
EVP, Chief Research OfficerOff |
• – – |
2023-07-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
7,316 |
|
-19% |
|
| Hirawat Samit |
EVP,Chief Med.Offr.,Drug Dev. |
• – – |
2023-07-01 |
4 |
D |
$63.95 |
$306,129 |
D/D |
(4,787) |
47,245 |
|
- |
|
| Hirawat Samit |
EVP,Chief Med.Offr.,Drug Dev. |
• – – |
2023-07-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,357 |
52,032 |
|
- |
|
| Weese Michelle |
EVP, Corporate Affairs |
• – – |
2023-07-01 |
4 |
D |
$63.95 |
$43,614 |
D/D |
(682) |
3,453 |
|
- |
|
| Weese Michelle |
EVP, Corporate Affairs |
• – – |
2023-07-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,885 |
4,135 |
|
- |
|
| Lenkowsky Adam |
EVP, Chief Commercial Officer |
• – – |
2023-06-03 |
4 |
D |
$65.66 |
$36,179 |
D/D |
(551) |
526 |
|
- |
|
| Lenkowsky Adam |
EVP, Chief Commercial Officer |
• – – |
2023-06-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,077 |
1,077 |
|
- |
|
| Vessey Rupert |
EVP & President, Research |
• – – |
2023-05-03 |
4 |
S |
$67.06 |
$3,378,818 |
D/D |
(50,385) |
47,751 |
|
10% |
|
| Greenlees Sharon |
SVP & Controller |
• – – |
2023-05-02 |
4 |
D |
$68.10 |
$23,563 |
D/D |
(346) |
609 |
|
- |
|
| Greenlees Sharon |
SVP & Controller |
• – – |
2023-05-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,017 |
728 |
|
- |
|
| Greenlees Sharon |
SVP & Controller |
• – – |
2023-05-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(62) |
627 |
|
- |
|
| Lenkowsky Adam |
EVP, Chief Commercial OfficerO |
• – – |
2023-04-26 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
10,048 |
|
-11% |
|
| Vessey Rupert |
EVP & President, Research |
• – – |
2023-03-10 |
4 |
D |
$65.71 |
$2,529,704 |
D/D |
(38,498) |
98,136 |
|
- |
|
| Vessey Rupert |
EVP & President, Research |
• – – |
2023-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
8,326 |
123,701 |
|
- |
|
| Vessey Rupert |
EVP & President, Research |
• – – |
2023-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
66,935 |
118,263 |
|
- |
|
| Shanahan Karin |
EVP, Glob. Prod. Dev. & Supply |
• – – |
2023-03-10 |
4 |
D |
$65.71 |
$60,059 |
D/D |
(914) |
1,612 |
|
- |
|
| Shanahan Karin |
EVP, Glob. Prod. Dev. & Supply |
• – – |
2023-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
79 |
2,526 |
|
- |
|
| Shanahan Karin |
EVP, Glob. Prod. Dev. & Supply |
• – – |
2023-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,447 |
2,447 |
|
- |
|
| Caforio Giovanni |
Board Chair and CEO |
• • – |
2023-03-10 |
4 |
D |
$65.71 |
$9,067,257 |
D/D |
(137,989) |
367,935 |
|
- |
|
2225 Records found
|
|
Page 3 of 89 |
|
|
0.15 (0.34%) 
